Denali Therapeutics and Biogen Initiate P-IIb (LUMA) Study of BIIB122 for the Treatment of Parkinson’s Disease
Shots:
- The P-IIb (LUMA) study evaluates the efficacy and safety of BIIB122 (DNL151) vs PBO in ~640 patients aged b/w 30 & 80yrs. with early-stage PD. The therapy was discovered and developed by Denali
- The 1EPs of the study are time to confirm worsening in MDS-UPDRS parts II & III combined score over the treatment period. The P-IIb (LUMA) & P-III (LIGHTHOUSE) studies in patients with PD caused by LRRK2 pathogenic mutations are part of the BIIB122 clinical development program
- BIIB122 is a selective, central nervous system-penetrant small molecule inhibitor of LRRK2 that is hypothesized to improve lysosomal dysfunction. The P-III (LIGHTHOUSE) study is expected to initiate in 2022
Ref:Biogen | Image: Biogen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
